默克公司称Molnupiravir在体外研究中积极对抗Omicron变体

07:14 AM EST, 01/28/2022 (MT Newswires) -- Merck & Company (MRK) and Ridgeback Biotherapeutics said Friday data from six preclinical studies show that molnupiravir is active against the omicron variant.

These in vitro studies employed established cell-based assays to assess the antiviral activity of the pill and other COVID-19 antiviral agents against SARS-CoV-2 variants of concern, including omicron. The studies included researchers from Belgium, the Czech Republic, Germany, Poland, the Netherlands, and the US, the companies said.

Molnupiravir is yet to be tested against omicron in clinical studies, the companies added.

The pill has already been authorized for use in more than 10 countries, including in the US, the UK, and Japan.

Price: 80.33, Change: -0.25, Percent Change: -0.31